Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06302348
Other study ID # PTC923-PKU-401
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date March 4, 2024
Est. completion date February 28, 2031

Study information

Verified date April 2024
Source PTC Therapeutics
Contact Patient Advocacy
Phone 1-866-562-4620
Email medinfo@ptcbio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main purpose of this trial is to evaluate the long-term efficacy of sepiapterin on preserving neurocognitive functioning in children with PKU when treatment is initiated in early childhood.


Description:

The study includes 2 parts: Part 1 and 2. Part 1 is a sepiapterin-responsiveness test, and Part 2 is an open-label treatment period.


Recruitment information / eligibility

Status Recruiting
Enrollment 56
Est. completion date February 28, 2031
Est. primary completion date February 28, 2031
Accepts healthy volunteers No
Gender All
Age group N/A to 12 Years
Eligibility Key Inclusion Criteria: - Women of childbearing potential must have a negative pregnancy test at screening and agree to abstinence or the use of at least one highly effective form of contraception for the duration of the study, and for up to 90 days after the last dose of the study drug. - Established diagnosis of PKU with hyperphenylalaninemia (HPA) evidenced by at least 1 blood Phe measurement >600 µmol/L as documented in the medical history. - For participants =1 month of age, a minimum of 1 documented blood Phe measurement <480 µmol/L within 1 month prior to Screening. - For participants =1 month of age, 2 screening blood Phe concentration values must be in the range =120 to =480 µmol/L. - Willing to continue prescribed diet during Screening and Part 1. - For participants =30 months to <12 years of age, baseline FSIQ score =80. Key Exclusion Criteria: - History of allergies or adverse reactions to synthetic tetrahydrobiopterin (BH4) or sepiapterin. - Serious neuropsychiatric illness (for example, major depression) not currently under medical control or other concurrent disease or condition that, in the opinion of the investigator or sponsor, would interfere with the participant's ability to participate in the study or increase the risk of participation for that participant. - Treatment with BH4 supplementation (sapropterin dihydrochloride, KUVAN) within 3 months prior to Screening. - Current participation in another investigational drug study or use of any investigational agent within 30 days prior to Screening. - Confirmed diagnosis of a primary BH4 deficiency as evidenced by biallelic pathogenic mutations in 6-pyruvoyltetrahydropterin synthase, recessive Guanosine-5'-triphosphate (GTP) cyclohydrolase I, sepiapterin reductase, quinoid dihydropteridine reductase, or pterin 4-alphacarbinolamine dehydratase genes. - Any clinically significant laboratory abnormality as determined by the investigator. - Any past medical history of an abnormal physical examination and/or laboratory findings indicative of signs or symptoms of renal disease, including calculated (Bedside Schwartz Equation) glomerular filtration rate (GFR) <60 milliliters (mL)/minute (min)/1.73 square meter (m^2). - Major surgery within the prior 90 days of Screening. Note: Other protocol-defined inclusion and exclusion criteria may apply.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sepiapterin
Sepiapterin powder for oral use will be suspended in water or apple juice prior to administration.

Locations

Country Name City State
United States Indiana University Indianapolis Indiana

Sponsors (1)

Lead Sponsor Collaborator
PTC Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Change From Baseline in Full-scale Intelligence Quotient (FSIQ) Weschler Preschool and Primary Scale of Intelligence - Fourth Edition (WPPSI-IV) Score Analysis for participants aged =30 months to <6 years. Baseline, Year 2
Primary Mean Change From Baseline in FSIQ Weschler Intelligence Scale for Children - Fifth Edition (WISC-V) Score Analysis for participants aged =6 years to 16 years. Baseline, Year 2
Secondary Change From Baseline in Phenylketonuria-Quality of Life (PKU-QOL) Questionnaire Score Baseline up to 4 years
Secondary Change From Baseline in the European Quality of Life - 5 Dimensions (EQ-5D) Score Baseline up to 4 years
Secondary Mean Change From Baseline in FSIQ (WPPSI-IV) Score Analysis for participants aged =30 months to <6 years. Baseline, Year 4
Secondary Mean Change From Baseline in FSIQ (WISC-V) Score Analysis for participants aged =6 years to 16 years. Baseline, Year 4
Secondary Change From Baseline in Mean Blood Phe Levels Baseline up to 6 years
See also
  Status Clinical Trial Phase
Completed NCT05099640 - A Study of PTC923 in Participants With Phenylketonuria Phase 3
Completed NCT01924026 - Neurocognitive Outcomes in Mild Hyperphenylalaninemia (MHP)MHP Study N/A
Completed NCT01428258 - Phase 2 Study of Glycomacropeptide Versus Amino Acid Diet for Management of Phenylketonuria N/A
Completed NCT00925054 - Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU Phase 2
Completed NCT00778206 - PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry
Recruiting NCT05948020 - Efficacy and Safety of Orally Administered Engineered Probiotics (CBT102-A) for the Treatment of Children With Phenylketonuria N/A
Recruiting NCT05781399 - First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria Phase 1
Completed NCT02555579 - Simplified Diet Approach in Phenylketonuria N/A
Completed NCT03097250 - MRI Spectroscopy and Neuropsychological Functioning in Phenylketonuria
Completed NCT01965912 - Kuvan®'s Effect on the Cognition of Children With Phenylketonuria Phase 4
Completed NCT01965691 - Protein Requirements in Children With Phenylketonuria (PKU) N/A
Completed NCT00688844 - Nutritional and Neurotransmitter Changes in PKU Subjects on BH4 N/A
Completed NCT00789568 - A Phase 1 Study to Evaluate Effects of Sapropterin Dihydrochloride on QTc Intervals in Healthy Adult Subjects Phase 1
Terminated NCT01465100 - Liver Cell Transplant for Phenylketonuria Phase 1/Phase 2
Completed NCT01732471 - Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria Phase 3
Completed NCT04879277 - Study of Low-grade Systemic Inflammation in Adult Patients With Phenylketonuria N/A
Completed NCT02176603 - Observational Study of Endothelial Dysfunction in Phenylketonuria N/A
Completed NCT01819727 - An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165 Phase 3
Completed NCT01869972 - Biological Variation of Phenylalanine in Patients With Hyperphenylalaninemia N/A
Terminated NCT01904708 - Moderate Intensity Exercise and Phenylketonuria N/A